People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Other Health Care, Pharma, Software / Tech, Other Technology, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| NeuMoDx Molecular, Inc. | — | Other Health Care | Series B | $54.8M | $444.0M | 2012 |
| Thorne Holding Corp. | — | Other Health Care | Series B | $45.7M | $281.4M | 2010 |
| Strata Oncology, Inc. | — | Pharma | Series A | $29.2M | $27.0M | 2016 |
| Tangent Medical Technologies, Inc. | — | Other Health Care | Series A | $23.0M | $20.2M | 2012 |
| Cycle Labs, Inc. | — | Software / Tech | Series A | $16.7M | $19.8M | 2022 |
| Exum Instruments, Inc. | — | Other Technology | Series A | $13.7M | $366K | 2019 |
| Accuri Cytometers Inc | — | Other Health Care | Series A | $9.7M | $121.1M | 2010 |
| e-Nicotine Technology, Inc. | — | Biotechnology | Seed | $7.0M | $17.8M | 2013 |
| Lucigen Corp | — | Biotechnology | Seed | $7.0M | $98.8M | 2012 |
| VitalMedix, Inc. | — | Biotechnology | Pre-Seed | $100K | $5.5M | 2009 |
Jeffrey Williams at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jeffrey Williams on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Timothy Petersen | 2 | 9 |
| Jan Garfinkle | 2 | 7 |
| Harry Wilcox | 2 | 6 |
| William Burkoth | 2 | 5 |
| Nicole Walker | 2 | 4 |
| Robert Weisskoff | 1 | 12 |
| David Rubin | 1 | 11 |
| Richard Williams | 1 | 10 |
| James Pavlik | 1 | 9 |
| Mark Wagner | 1 | 9 |
| Christopher O'Donnell | 1 | 8 |
| Richard Brenner | 1 | 6 |
| Edward Michael | 1 | 6 |
| James Thorson | 1 | 5 |
| George Dunbar | 1 | 5 |
| Doug Johnson | 1 | 5 |
| Timothy B. Petersen | 1 | 5 |
| Peter Shagory | 1 | 5 |
| Keith Flaherty | 1 | 5 |
| Timothy McLoughlin | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.